Specialty Dosage Drugs

Nov 01, 2010
Pharmaceutical Technology Europe
By Pharmaceutical Technology Editors
Although there are no regulatory requirements or established pharmacopoeial techniques for the dissolution testing of inhaled drugs, such testing can potentially open up the opportunity to tailor formulation properties.
Nov 01, 2010
Pharmaceutical Technology
By Pharmaceutical Technology Editors
The author reviews key considerations for formulating powders for use in inhalers. This article is part of a special Drug Delivery issue.
Sep 15, 2010
Equipment and Processing Report
By Pharmaceutical Technology Editors
US Pharmacopeia apparatuses for testing the dissolution of transdermal drugs produce good, reproducible results. Yet some scientists believe that further modifications could improve the instruments? suitability for this application.
Aug 05, 2010
ePT--the Electronic Newsletter of Pharmaceutical Technology
By Pharmaceutical Technology Editors
In a draft guidance published this week, the US Food and Drug Administration recommended that makers of transdermal and transmucosal drug-delivery systems use "an appropriate scientific approach" during product design, development, and manufacturing to minimize the amount of residual drug substance present at the end of the products' labeled use periods.
Jul 21, 2010
Equipment and Processing Report
By Pharmaceutical Technology Editors
The pharmaceutical industry?s increasing interest in inhaled drugs has prompted several researchers to propose standard dissolution-testing methods for these products.
May 02, 2010
Pharmaceutical Technology
By Pharmaceutical Technology Editors
The authors demonstrate that sustained-release delivery can help avoid the risk of sudden higher-blood concentration of a drug to avoid toxicity.
Apr 22, 2010
ePT--the Electronic Newsletter of Pharmaceutical Technology
After several years of debate and review, the US Food and Drug Administration is calling for the removal of metered-dose inhalers.
Jan 01, 2010
Pharmaceutical Technology Europe
Transdermal drug delivery is valued by patients and physicians for the comfort and convenience it offers — no needles, no pills and ease of use
Jan 01, 2010
Pharmaceutical Technology Europe
By Pharmaceutical Technology Editors
Only around 10–20% of asthma medications are delivered to the lungs because of the barrier-nature of the respiratory tract and medication loss in the inhaler during the inhalation process.
Nov 06, 2009
Pharmaceutical Technology Europe
The European Organisation for Rare Diseases (EURORDIS) has predicted that 100 new designated orphan products will receive marketing authorization between 2009 and 2019, which equates to approximately 10 new products every year.
native1_300x100
lorem ipsum